# Project 01 â€“ Simulated ICSR Case Processing & Regulatory Assessment

## ğŸ“Œ Project Overview

This project simulates end-to-end Individual Case Safety Report (ICSR) processing to demonstrate structured pharmacovigilance workflow aligned with international drug safety standards.

A total of 20 simulated and de-identified ICSRs were processed using regulatory assessment principles applicable to both India (PvPI/CDSCO) and global environments (FDA/EMA).

---

## ğŸ¯ Project Objective

To demonstrate practical competency in:

- Case intake and evaluation
- MedDRA coding hierarchy application (LLT â†’ PT â†’ SOC)
- Seriousness assessment using ICH E2A criteria
- Expectedness evaluation (label-based assumption)
- WHO-UMC causality assessment
- Expedited reporting decision-making
- Regulatory timeline determination (7 / 15 / 90 days)
- Professional case narrative drafting
  
---

## ğŸ§ª Workflow Followed

### 1ï¸âƒ£ Case Review
Each case was evaluated for:
- Patient demographics
- Suspected drug
- Concomitant medications
- Event onset
- Outcome

### 2ï¸âƒ£ MedDRA Coding
Reported adverse events were mapped to:
- LLT (Lowest Level Term)
- PT (Preferred Term)
- SOC (System Organ Class)

Coding was performed using publicly available terminology for educational purposes.

### 3ï¸âƒ£ Seriousness Assessment
Applied ICH E2A seriousness criteria:
- Death
- Life-threatening
- Hospitalization
- Disability
- Congenital anomaly
- Medically significant condition

### 4ï¸âƒ£ Expectedness Evaluation
Events were assessed as expected or unexpected based on assumed product label knowledge.

### 5ï¸âƒ£ Causality Assessment
WHO-UMC system applied:
- Certain
- Probable
- Possible
- Unlikely

### 6ï¸âƒ£ Regulatory Reporting Logic
Determined reporting timelines:

- Fatal / Life-threatening â†’ 7 calendar days
- Other serious â†’ 15 calendar days
- Non-serious â†’ 90 days

Applicable to both India and global regulatory frameworks.

### 7ï¸âƒ£ Case Narrative Drafting
Each case was summarized in structured, regulatory-compliant narrative format suitable for PV documentation.

---

## ğŸ“˜ Regulatory References

- ICH E2A â€“ Clinical Safety Data Management
- ICH E2B (R3) â€“ Electronic Transmission of ICSRs
- WHO-UMC Causality Assessment System
- PvPI (India) Reporting Framework
- FDA & EMA Post-Marketing Reporting Principles

---

## ğŸ›  Tools Used

- Microsoft Excel â€“ Structured assessment and documentation
- Microsoft Word â€“ Narrative drafting
- GitHub â€“ Documentation and portfolio presentation

---

## ğŸ“Š Skills Demonstrated

- Regulatory reasoning
- Clinical interpretation of adverse events
- Structured safety documentation
- Analytical decision-making
- Risk-based evaluation thinking

---

## âš  Disclaimer

All cases included in this project are simulated and created exclusively for educational and portfolio development purposes.

No real patient data, proprietary safety databases, or confidential pharmaceutical information are used.

---

## ğŸ“‚ Project Structure

